CASE CCC IN THE NEWS
Cleveland Clinic Immunologist Presents Preventive Vaccine Research to Breast Cancer Field for 1st Time
The Plain Dealer - Dec 13, 2013
More than three years after his research on a potential breast cancer vaccine appeared in the scientific journal Nature Medicine, Cleveland Clinic immunologist and Case Comprehensive Cancer Center member Vincent Tuohy is finally presenting his work to the scientific breast cancer community...
Research roundup: News from the 2013 San Antonio Breast Cancer Symposium
The Plain Dealer - Dec 13, 2013
Initial research findings from University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center are shedding new light on how changes in breast cancer tumors, after just one dose of biologic therapy or chemotherapy, can predict a patient's prognosis. Led by Dr. Lyndsay Harris, director of UH Seidman's Breast Cancer Program, the researchers found that through deep genome sequencing (a process that identifies mutations within tumors in a specific region), they could observe a reduction in the most commonly mutated genes in breast cancer after just one dose of preoperative therapy.
Energy Efficient Light Bulbs Could Pose UV-risk to Skin, Trigger Migraines
Fox News - Dec 13, 2013
Broader use of compact fluorescents (CFLs) may actually come with some unwanted health risks – most notably in regards to people's skin..."Ultraviolet light is similar to the ultraviolet wavelengths found in natural sunlight, and we do not want huge amounts or extra amounts of ultraviolet light on our skin because it can cause biological effects that can lead to cancer," Dr. Elma Baron, director in the lasers and photomedicine department at UH Case Medical Center in Cleveland and member of the Case Comprehensive Cancer Center, told FoxNews.com.
Early Warning Signs of Cancer: Are You at Risk?
Yahoo Health - Dec 10, 2013
It's tragically common for patients to ignore warnings of other types of cancer, adds Dale Shepard, MD, PhD, a cancer specialist in the department of solid tumor oncology at the Cleveland Clinic and member of the Case Comprehensive Cancer Center. "Cancer can almost always be cured if it's caught early, but all too often, people wait so long to see a doctor that the disease has spread to the point that it's no longer curable."
SAVE THE DATE
Case CCC Annual Scientific Retreat
Please mark your calendars for the Case CCC Annual Scientific Retreat, July 10-11, 2014. More details to come!
Case CCC Leadership Awards
Every year at the Cancer Center Holiday Party we recognize an outstanding Cancer Center leader for their efforts. This year, Chris Flask, PhD was recognized for dedicating his time and effort to improving the quality and support of the cores in the Cancer Center and in the medical school.Amitabh Chak, MD was also recognized for his efforts to facilitate tissue-based research in the Cancer Center and for accepting the responsibility to chair the tissue research review committee. Both Drs. Flask and Chak received a clock to commemorate their award.
Vote for Dr. Stan Gerson for the AACR Nominating Committee
Our director, Dr. Stan Gerson, is on the ballot for the American Association for Cancer Research (AACR) Nominating Committee. The election opens today, December 16 and will close on Friday, February 14, 2014. Voting instructions will be distributed to all voting members of AACR. Election results will be announced in March 2014 and elected candidates will assume office at the AACR Annual Meeting 2014 in April.
Please show your support for Dr. Gerson and vote for him! It would be great to have local votes that place our director on the Nominating Committee, which selects candidates for major awards, the annual meeting program committee, and the slate of candidates for national positions.
The Gene Expression and Genotyping (GEGF) Core Facility would like to let you know about an attractive promotion that Affymetrix is offering on their new and very exciting Human Transcriptome Array (HTA). This array, which assesses total gene expression and alternative splicing transcripts, is an extremely competitive, budget-friendly alternative platform to RNA sequencing. The technology is capable of handling RNA from Fresh, Frozen and FFPE materials and works with starting amounts as little as 50ng of totRNA. Click here for more details and a comparison of RNAseq and the HTA microarray platform. You can also visit the Affymetrix web site for more information on the HTA Expression Product.
Details of Affymetrix Promotion:
Sample Isolated from Fresh or Frozen Tissue: Out the door price (includes sample processing, reagents & array)= $390/sample
Promotion expires Friday, Dec 27: Price will then increase to $500/sample
Sample Isolated from FFPE Material: Out the door price (includes sample processing, reagents & array)=$490/sample
Promotion expires Friday, Dec 27: Price will then increase to $600/sample
Note: Additional processing discounts are available for larger studies. Please inquire.
If you wish to avail yourself of this promotion, contact Debora Poruban at 368-8748 or firstname.lastname@example.org by close of day Friday, December 27. Questions about the technology: Contact Marty Veigl at (216.368.5689 or email@example.com) or Patrick Leahy (216.368.0761 or firstname.lastname@example.org).
P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs)
The NIH is accepting applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). Case CCC administration is available to assist with planning and submission of SPORE applications.
This Funding Opportunity Announcement invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer (or a related group of cancers). SPOREs are expected not only to conduct a wide spectrum of research activities, but also to contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research projects with other institutions. The research supported through this program must be translational in nature and must always be focused upon knowledge of human biology stemming from research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches with the goal of a translational human endpoint within the project period of the grant. In addition, SPOREs must include both a Developmental Research Program for pilot studies and a Career Development Program to foster careers in organ-based translational science.
Application Deadlines: February 13, 2014; May 20, 2014; September 23, 2014
New Connections: Increasing Diversity of RWJF Programming
The Robert Wood Johnson Foundation New Connections program provides support and training to Junior Investigators and Mid-Career Consultants to address priorities related to RWJF's program areas: Childhood Obesity, Coverage, Human Capital, Pioneer, Public Health, Quality/Equality and Vulnerable Populations. This round of New Connections funding will focus on research projects addressing health disparities.
Proposal Deadline: January 15, 2014
Avon Foundation Breast Cancer Research Program
To develop new strategies to prevent breast cancer, we need to understand the causes of breast cancer in people, changes in breast cells that give rise to cancer, markers for disease, and how breast cancer progresses. The 2014 Avon Foundation Research Program seeks proposals in these areas to advance understanding of causes of breast cancer and prevention.
LOI Deadline: January 31, 2014
Application Deadline: March 28, 2014